NanoViricides (NNVC)
XASE:NNVC
Top Page
NanoViricides
(NYSE MKT:NNVC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-11.50% Downside)
Action:ReiteratedDate:03/12/26
The score is primarily held down by weak financial performance (no revenue, sustained losses, and consistent cash burn with likely ongoing funding needs). Technical indicators provide a modest offset via improving short-term momentum, but valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Proprietary nanoviricide platform & in-house manufacturing
NanoViricides’ proprietary nanoviricide platform and in-house manufacturing capabilities create a durable technological and operational advantage. Platform-based antiviral approaches allow reuse of core chemistry across indications, while internal manufacturing reduces vendor dependency and supports controlled scale-up once clinical proof is achieved, aiding long-term commercialization potential.
Negative Factors
No commercial revenue
Lack of any commercial revenue leaves the business dependent entirely on external financing and milestone/partner payments. Without product sales, the company carries binary clinical and regulatory risk for revenue realization, making long-term viability contingent on successful trials, partnerships, or asset sales rather than operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary nanoviricide platform & in-house manufacturing
NanoViricides’ proprietary nanoviricide platform and in-house manufacturing capabilities create a durable technological and operational advantage. Platform-based antiviral approaches allow reuse of core chemistry across indications, while internal manufacturing reduces vendor dependency and supports controlled scale-up once clinical proof is achieved, aiding long-term commercialization potential.
Read all positive factors
NanoViricides (NNVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.46M
Dividend YieldN/A
Average Volume (3M)143.34K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue GrowthN/A
EPS Growth32.92%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding21,595,000
10 Day Avg. Volume199,739
30 Day Avg. Volume143,335
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap-229.33K
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.88M
Enterprise Value/Ebitda667.80K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)N/A
NanoViricides Business Overview & Revenue Model
Company Description
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus a...
How the Company Makes Money
null...
NanoViricides Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -324.27K | 0.00 | 0.00 | -747.53K | 0.00 | 0.00 |
| EBITDA | -7.71M | -8.72M | -7.49M | -7.84M | -7.38M | -8.04M |
| Net Income | -8.32M | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M |
Balance Sheet | ||||||
| Total Assets | 12.27T | 8.82M | 12.82M | 16.90M | 23.49M | 30.26M |
| Cash, Cash Equivalents and Short-Term Investments | 5.15T | 1.56M | 4.80M | 8.15M | 14.07M | 20.52M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 94.79K | 95.31K |
| Total Liabilities | 1.20T | 1.31M | 1.36M | 2.03M | 412.84K | 351.15K |
| Stockholders Equity | 11.07T | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M |
Cash Flow | ||||||
| Free Cash Flow | -3.73T | -8.54M | -6.47M | -5.82M | -6.22M | -8.45M |
| Operating Cash Flow | -3.64T | -8.48M | -6.32M | -5.67M | -5.89M | -8.21M |
| Investing Cash Flow | -94.52K | -56.96K | -156.56K | -151.71K | -324.35K | -238.76K |
| Financing Cash Flow | 8.62M | 5.30M | 3.12M | -94.79K | -234.72K | 15.26M |
NanoViricides Technical Analysis
Positive
1.13
Price Trends
1.00
Positive
1.10
Negative
1.31
Negative
Market Momentum
<0.01
Negative
52.54
Neutral
49.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NNVC, the sentiment is Positive. The current price of 1.13 is above the 20-day moving average (MA) of 1.00, above the 50-day MA of 1.00, and below the 200-day MA of 1.31, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.54 is Neutral, neither overbought nor oversold. The STOCH value of 49.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NNVC.
NanoViricides Risk Analysis
NanoViricides disclosed 51 risk factors in its most recent earnings report. NanoViricides reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NanoViricides Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $198.71M | 5.44 | -21.16% | ― | -92.42% | 62.37% | |
46 Neutral | $14.51M | -1.17 | ― | ― | ― | 79.31% | |
45 Neutral | $22.46M | -2.53 | -94.03% | ― | ― | 32.92% | |
44 Neutral | $198.97M | 0.03 | -62.91% | ― | ― | 46.09% | |
42 Neutral | $4.81M | -0.46 | -68.21% | ― | ― | ― |
* Healthcare Sector Average
NNVC
NanoViricides
1.04
-0.36
-25.71%
ENLV
Enlivex
0.82
-0.04
-5.12%
AKTX
Akari Therapeutics
4.63
-39.37
-89.48%
MBRX
Moleculin Biotech
2.49
-20.49
-89.16%
SABS
SAB Biotherapeutics
3.86
2.47
177.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.